Skip to main content

Advertisement

SpringerLink
Log in

Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy

  • Case Report
  • Published:
Emergency Radiology Aims and scope Submit manuscript

Abstract

We present a case of a 58-year-old female with anti-PD-1 immunotherapy-related small bowel perforation. The patient was on long-term therapy with nivolumab for metastatic non-small cell lung cancer. She presented to the emergency department with acute abdominal pain, in which the CT revealed a short segment of dilated distal ileum proximal to a very short segment of bowel with mural thickening and a perforation near the transition point. The patient underwent subsequent laparotomy, which confirmed the CT findings and revealed a short-segment of friable and dilated loop of distal ileum proximal to a stricture and a small perforation at the transition point. Pathological analysis revealed mural thickening at the site of stricture without evidence of malignancy with focal necrosis and perforation at the transition point. Bowel perforation in the setting of anti-PD-1 immunotherapy is rare, but life-threatening complication, and should be considered in oncology patients on immunotherapy presenting with severe abdominal pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yasuda K, Tanaka T, Ishihara S, Otani K, Nishikawa T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Masui Y, Shintani Y, Watanabe T (2017) Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surg Case Rep 3(1):94

    Article  Google Scholar 

  2. Wei W, Luo Z (2017) Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: a meta-analysis of randomized clinical trials. Medicine 96(48):e8931

    Article  CAS  Google Scholar 

  3. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030

    Article  CAS  Google Scholar 

  4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639

    Article  CAS  Google Scholar 

  5. Guan M, Zhou Y-P, Sun J-L, Chen S-C. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int 2015:428169, 1, 13

    Google Scholar 

  6. Arora N, Gupta A, Singh PP (2017) Biological agents in gastrointestinal cancers: adverse effects and their management. J Gastrointest Oncol 8(3):485–498

    Article  Google Scholar 

  7. Areses Manrique MC, Mosquera Martínez J, García González J, Afonso Afonso FJ, Lázaro Quintela M, Fernández Núñez N, Azpitarte Raposeiras C, Amenedo Gancedo M, Santomé Couto L, García Campelo MR, Muñoz Iglesias J, Cortegoso Mosquera A, Vilchez Simo R, Casal Rubio J, Campos Balea B, Carou Frieiro I, Alonso-Jaudenes Curbera G, Anido Herranz U, García Mata J, Fírvida Pérez JL (2018) Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. Transl Lung Cancer Res 7(3):404–415

    Article  Google Scholar 

  8. Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, Kuwaki K, Mori A, Yoshimura T, Tsuruta O, Torimura T (2018) The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol 18(1):135

    Article  Google Scholar 

  9. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Emergency Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    David K. Tso, Laura L. Avery, Michael H. Lev & Shamir Kamalian

Authors
  1. David K. Tso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura L. Avery
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael H. Lev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shamir Kamalian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David K. Tso.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tso, D.K., Avery, L.L., Lev, M.H. et al. Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy. Emerg Radiol 27, 107–110 (2020). https://doi.org/10.1007/s10140-019-01731-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10140-019-01731-x

Keywords

Search

Navigation